Evidence map›Paper›PMID 31004214›Full record

ArticleJournal of neurology2019

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation.

Zoé L E van Kempen, Johannis A van Rossum, Djoeke Doesburg, Iris Claessen, Annick de Vries, Anja Ten Brinke, Bob W van Oosten, Theo Rispens, Joep Killestein

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zoé L E van KempenDepartment of Neurology, Neuroscience Amsterdam, Amsterdam MS Center, Amsterdam University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. z.vankempen@vumc.nl.ORCID 0000-0001-9557-5381
Johannis A van RossumDepartment of Neurology, Neuroscience Amsterdam, Amsterdam MS Center, Amsterdam University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Djoeke DoesburgDepartment of Neurology, Neuroscience Amsterdam, Amsterdam MS Center, Amsterdam University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Iris ClaessenDepartment of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
Annick de VriesDepartment of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
Anja Ten BrinkeDepartment of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
Bob W van OostenDepartment of Neurology, Neuroscience Amsterdam, Amsterdam MS Center, Amsterdam University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Theo RispensDepartment of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
Joep KillesteinDepartment of Neurology, Neuroscience Amsterdam, Amsterdam MS Center, Amsterdam University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntibodiesFemaleHumansImmunologic FactorsIntegrin alpha4Multiple Sclerosis, Relapsing-RemittingNatalizumabAntibodiesImmunologic FactorsIntegrin alpha4Natalizumab

Identifiers

PMID31004214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.